$ERNA Income Statement | Understand Stock

$ERNA

$1.94 -$0.13 (6.15%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Cost of revenues
Gross profit
Operating expenses:
Research and development
Acquired in-process research and development
General and administrative
Transaction costs
Change in fair value of contingent consideration
Impairment of in-process research and development
Gain on lease termination
Acquisition of Exacis in-process research and development
Total operating expenses

Loss from operations
Loss on sale of NTN assets
Other expense, net:
Forward sales contract expense
Loss on extinguishment of debt
Change in fair value of convertible notes
Change in fair value of bridge notes derivative liability
Change in fair value to bridge notes derivative liability
Change in fair value of warrant liabilities
Change in fair value of contingent consideration
Loss on non-controlling investment
Interest income
Interest expense
Other income, net
Total other expense, net
Loss before income taxes
Benefit (provision) for income taxes
Net loss
Series A preferred stock dividend
Net loss attributable to common stockholders
Net loss per common share - basic
Net loss per common share - diluted
Weighted average shares outstanding - basic
Weighted average shares outstanding - diluted

Comments